Exploring and comparing adverse events between PARP inhibitors

Christopher J. LaFargue, Graziela Z. Dal Molin, Anil K Sood, Robert Coleman

Research output: Contribution to journalReview article

Abstract

Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a functional homologous recombination repair pathway. Perhaps the most advantageous characteristic of PARP inhibitors is their mechanism of action, which targets cancer cells on the basis of their inherent deficiencies while seemingly avoiding normally functioning cells. Although health-care providers might assume a low toxicity profile because of their specific mechanism of action, PARP inhibitors are not completely benign and overall show a class effect adverse-event profile. Further complicating this situation, three different PARP inhibitors have been approved by the US Food and Drug Administration since 2014, each with their own specific indications and individual toxicity profiles. The diversity of adverse events seen both within and across this class of drug underscores the importance of having a comprehensive reference to help guide clinical decision making when treating patients. This Review characterises and compares all toxicities associated with each PARP inhibitor, both in monotherapy and in novel combinations with other drugs, with a particular focus on potential management strategies to help mitigate toxic effects. Although the excitement surrounding PARP inhibitors might certainly be warranted, a thorough understanding of all associated toxicities is imperative to ensure that patients can achieve maximal clinical benefit.

Original languageEnglish (US)
Pages (from-to)e15-e28
JournalThe lancet oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ovarian Neoplasms
Recombinational DNA Repair
Poisons
United States Food and Drug Administration
Pharmaceutical Preparations
Health Personnel
Poly(ADP-ribose) Polymerase Inhibitors
Neoplasms
Mutation
Therapeutics
Clinical Decision-Making

ASJC Scopus subject areas

  • Oncology

Cite this

Exploring and comparing adverse events between PARP inhibitors. / LaFargue, Christopher J.; Dal Molin, Graziela Z.; Sood, Anil K; Coleman, Robert.

In: The lancet oncology, Vol. 20, No. 1, 01.01.2019, p. e15-e28.

Research output: Contribution to journalReview article

LaFargue, Christopher J. ; Dal Molin, Graziela Z. ; Sood, Anil K ; Coleman, Robert. / Exploring and comparing adverse events between PARP inhibitors. In: The lancet oncology. 2019 ; Vol. 20, No. 1. pp. e15-e28.
@article{73cb7bf8fbee489da295bbbc2921a50d,
title = "Exploring and comparing adverse events between PARP inhibitors",
abstract = "Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a functional homologous recombination repair pathway. Perhaps the most advantageous characteristic of PARP inhibitors is their mechanism of action, which targets cancer cells on the basis of their inherent deficiencies while seemingly avoiding normally functioning cells. Although health-care providers might assume a low toxicity profile because of their specific mechanism of action, PARP inhibitors are not completely benign and overall show a class effect adverse-event profile. Further complicating this situation, three different PARP inhibitors have been approved by the US Food and Drug Administration since 2014, each with their own specific indications and individual toxicity profiles. The diversity of adverse events seen both within and across this class of drug underscores the importance of having a comprehensive reference to help guide clinical decision making when treating patients. This Review characterises and compares all toxicities associated with each PARP inhibitor, both in monotherapy and in novel combinations with other drugs, with a particular focus on potential management strategies to help mitigate toxic effects. Although the excitement surrounding PARP inhibitors might certainly be warranted, a thorough understanding of all associated toxicities is imperative to ensure that patients can achieve maximal clinical benefit.",
author = "LaFargue, {Christopher J.} and {Dal Molin}, {Graziela Z.} and Sood, {Anil K} and Robert Coleman",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(18)30786-1",
language = "English (US)",
volume = "20",
pages = "e15--e28",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Exploring and comparing adverse events between PARP inhibitors

AU - LaFargue, Christopher J.

AU - Dal Molin, Graziela Z.

AU - Sood, Anil K

AU - Coleman, Robert

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a functional homologous recombination repair pathway. Perhaps the most advantageous characteristic of PARP inhibitors is their mechanism of action, which targets cancer cells on the basis of their inherent deficiencies while seemingly avoiding normally functioning cells. Although health-care providers might assume a low toxicity profile because of their specific mechanism of action, PARP inhibitors are not completely benign and overall show a class effect adverse-event profile. Further complicating this situation, three different PARP inhibitors have been approved by the US Food and Drug Administration since 2014, each with their own specific indications and individual toxicity profiles. The diversity of adverse events seen both within and across this class of drug underscores the importance of having a comprehensive reference to help guide clinical decision making when treating patients. This Review characterises and compares all toxicities associated with each PARP inhibitor, both in monotherapy and in novel combinations with other drugs, with a particular focus on potential management strategies to help mitigate toxic effects. Although the excitement surrounding PARP inhibitors might certainly be warranted, a thorough understanding of all associated toxicities is imperative to ensure that patients can achieve maximal clinical benefit.

AB - Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a functional homologous recombination repair pathway. Perhaps the most advantageous characteristic of PARP inhibitors is their mechanism of action, which targets cancer cells on the basis of their inherent deficiencies while seemingly avoiding normally functioning cells. Although health-care providers might assume a low toxicity profile because of their specific mechanism of action, PARP inhibitors are not completely benign and overall show a class effect adverse-event profile. Further complicating this situation, three different PARP inhibitors have been approved by the US Food and Drug Administration since 2014, each with their own specific indications and individual toxicity profiles. The diversity of adverse events seen both within and across this class of drug underscores the importance of having a comprehensive reference to help guide clinical decision making when treating patients. This Review characterises and compares all toxicities associated with each PARP inhibitor, both in monotherapy and in novel combinations with other drugs, with a particular focus on potential management strategies to help mitigate toxic effects. Although the excitement surrounding PARP inhibitors might certainly be warranted, a thorough understanding of all associated toxicities is imperative to ensure that patients can achieve maximal clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=85059348677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059348677&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30786-1

DO - 10.1016/S1470-2045(18)30786-1

M3 - Review article

VL - 20

SP - e15-e28

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -